Bryant D. Lim
2023 - Prelude Therapeutics
In 2023, Bryant D. Lim earned a total compensation of $1.6M as Chief Legal Officer, Corporate Secretary, and Interim Chief Financial Officer at Prelude Therapeutics.
Compensation breakdown
| Non-Equity Incentive Plan | $159,083 |
|---|---|
| Option Awards | $1,086,904 |
| Salary | $359,282 |
| Other | $9,497 |
| Total | $1,614,766 |
Lim received $1.1M in option awards, accounting for 67% of the total pay in 2023.
Lim also received $159.1K in non-equity incentive plan, $359.3K in salary and $9.5K in other compensation.
Rankings
In 2023, Bryant D. Lim's compensation ranked 724th out of 2,978 executives tracked by ExecPay. In other words, Lim earned more than 75.7% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 724 out of 2,978 | 76th |
Division Manufacturing | 413 out of 1,637 | 75th |
Major group Chemicals And Allied Products | 279 out of 906 | 69th |
Industry group Drugs | 273 out of 869 | 69th |
Industry Pharmaceutical Preparations | 179 out of 627 | 72nd |
Source: SEC filing on April 26, 2024.
Lim's colleagues
We found two more compensation records of executives who worked with Bryant D. Lim at Prelude Therapeutics in 2023.
News
Prelude Therapeutics CEO Krishna Vaddi's 2023 pay slips 20% to $2.6M
April 26, 2024
Idera Pharmaceuticals CEO Vincent Milano's 2020 pay rises 1% to $1.3M
April 28, 2021
Idera Pharmaceuticals CEO Vincent Milano's 2019 pay falls 25% to $1.3M
April 6, 2020
Idera Pharmaceuticals CEO Vincent Milano's 2018 pay jumps 49% to $1.8M
April 25, 2019